Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06087640 · ClinicalTrials.gov registry record · Phase 3
A Clinical Study to Evaluate the Efficacy, Safety and Immunogenicity of an Adjuvanted Influenza Vaccine Compared to a Non-adjuvanted Influenza Vaccine in Adults ≥65 Years of Age
A Phase 3 study of Influenza, Human, sponsored by Seqirus.
- Active
- Registry status
- Phase 3
- Development phase
- 35,800
- Enrollment target
- 20
- Study locations
NCT06087640 is a Phase 3 study of Influenza, Human that is active but no longer recruiting, run by Seqirus. The registered enrollment target is 35,800 participants, above the 14,235-participant average among 18 other Influenza, Human trials with a reported enrollment target (151% higher). The trial reports 20 study locations across 6 states.
The verdict
NCT06087640, a Phase 3 study of Influenza, Human, is active but no longer recruiting, sponsored by Seqirus.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 3
- Development phase
- 35,800 participants
- Enrollment target
- 20
- Study locations
Study Summary
This Phase 3 study is a randomized, observer-blind study of MF59-adjuvanted influenza vaccine (aQIV or aTIV) compared with a non-adjuvanted influenza vaccine (QIV or TIV) in adults ≥65 years of age. The aim of the study is to evaluate MF59-adjuvanted influenza vaccine compared with non-adjuvanted influenza vaccine in the prevention of reverse transcription-polymerase chain reaction (RT-PCR)-confirmed influenza A and/or B in subjects ≥65 years of age.
Conditions Studied
Interventions
- BIOLOGICAL aQIV or aTIV
- BIOLOGICAL QIV or TIV
Study Locations (20)
California
- 84101-West Coast Research LLC - Dublin
- 84124-Leading Edge Research - Encino
- 84104-Zillan Clinical Research - Inglewood
- 84105-Eximia Research - CA - La Mesa
- 84107-Long Beach Research Institute - Long Beach
- 84109-Long Beach Clinical Trials - Long Beach
- 84115-Central Valley Research - Modesto
- 84120-Paradigm Research - Redding
- 84119-Apex Clinical Research - San Diego
Colorado
- 84125-Lynn Institute of Denver - Aurora
- 84110-Tekton Research - Longmont
- 84123-Paradigm Research - Wheat Ridge
Alabama
- 84046-Accel Research Sites - Birmingham - Birmingham
- 84075-Cullman Clinical Trials - Cullman
Arizona
- 84112-DM Clinical Research - Phoenix - Phoenix
- 84114-Scottsdale Clinical Trials - Scottsdale
Arkansas
- 84045-Lynn Institute of the Ozarks - Little Rock
- 84070-Baptist Health Center for Clinical Research - Little Rock
Connecticut
- 84085-Clinical Research Consulting, LLC - Milford
- 84017-Chase Medical Research, LLC - Waterbury
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 35,800 participants |
| Start Date | 2023-10-23 |
| Est. Completion | 2026-12 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06087640
The ClinicalTrials.gov registry entry for NCT06087640 describes a study currently listed as active not recruiting, categorized as Phase 3. The registered enrollment target is 35,800 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 14,235-participant average among 18 other Influenza, Human trials with a reported enrollment target (151% higher). The listed sponsor is Seqirus, which has 25 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Influenza, Human appearing as the primary indexed condition, and to 2 interventions - of which aQIV or aTIV is the first listed.
NCT06087640 reports 20 study locations spanning 6 distinct geographic areas - top geographies include California, Colorado, Alabama.
Frequently Asked Questions
What is clinical trial NCT06087640 about?
NCT06087640 is a clinical study titled "A Clinical Study to Evaluate the Efficacy, Safety and Immunogenicity of an Adjuvanted Influenza Vaccine Compared to a Non-adjuvanted Influenza Vaccine in Adults ≥65 Years of Age". This Phase 3 study is a randomized, observer-blind study of MF59-adjuvanted influenza vaccine (aQIV or aTIV) compared with a non-adjuvanted influenza vaccine (QIV or TIV) in adults ≥65 years of age. The aim of the study is to evaluate MF59-adjuvanted influenza vaccine compared with non-adjuvanted in...
What is the current status of trial NCT06087640?
This trial is currently active not recruiting. It is a Phase 3 study. The enrollment target is 35,800 participants. The study started on 2023-10-23. Estimated completion is 2026-12.
What conditions does trial NCT06087640 study?
This clinical trial studies the following conditions: Influenza, Human.
What interventions are being tested in trial NCT06087640?
The interventions under investigation include: aQIV or aTIV (BIOLOGICAL), QIV or TIV (BIOLOGICAL).
Who is sponsoring clinical trial NCT06087640?
This trial is sponsored by Seqirus, which has 25 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06087640 being conducted?
This trial has 20 study locations across Alabama, Arizona, Arkansas, California, Colorado. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Influenza, Human
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Study to Evaluate the Immunogenicity and Safety of Seqirus Quadrivalent Influenza Vaccine (QIV) in a Pediatric Population 6 Months Through 59 Months of Age.
COMPLETED · Phase 3
-
A Study of Oseltamivir (Tamiflu) for Treatment of Influenza in Immunocompromised Participants.
COMPLETED · Phase 3
-
A Study of Intravenous Zanamivir Versus Oral Oseltamivir in Adults and Adolescents Hospitalized With Influenza
COMPLETED · Phase 3
-
A Clinical Study to Evaluate the Immunogenicity and Safety of an Adjuvanted Quadrivalent Influenza Vaccine Compared With a Licensed Quadrivalent Vaccine in Adults 50 to 64 Years of Age
COMPLETED · Phase 3
-
A Study to Evaluate the Immune Response and Safety of an Influenza Vaccine in Adults 18 Years of Age and Above
RECRUITING · Phase 2
-
Characterization of Humoral and Cellular Immune Responses Elicited by Influenza Vaccination in Healthy Adults
RECRUITING · Phase 4
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.